UOC
SWTX

UBS O'Connor’s SpringWorks Therapeutics SWTX Stock Holding History

UBS O'Connor’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,385,517
Closed -$65.1M – 434
2025
Q2 		$65.1M Buy
1,385,517
+1,346,549
+3,456% +$59.9M 1.77% 14
2025
Q1 		$1.72M Sell
38,968
-2,525
-6% -$116K 0.04% 139
2024
Q4 		$1.5M Buy
41,493
+12,980
+46% +$454K 0.04% 190
2024
Q3 		$914K Sell
28,513
-3,701
-11% -$138K 0.02% 291
2024
Q2 		$1.21M Sell
32,214
-15,036
-32% -$633K 0.03% 271
2024
Q1 		$2.33M Sell
47,250
-28,000
-37% -$1.29M 0.07% 153
2023
Q4 		$2.75M Sell
75,250
-17,986
-19% -$469K 0.09% 129
2023
Q3 		$2.16M Sell
93,236
-22,397
-19% -$612K 0.04% 235
2023
Q2 		$3.03M Buy
115,633
+16,053
+16% +$422K 0.06% 191
2023
Q1 		$2.56M Sell
99,580
-12,035
-11% -$352K 0.06% 230
2022
Q4 		$2.9M Buy
111,615
+21,622
+24% +$533K 0.05% 321
2022
Q3 		$2.57M Buy
89,993
+8,500
+10% +$244K 0.03% 488
2022
Q2 		$2.01M Buy
81,493
+59,893
+277% +$2.19M 0.02% 652
2022
Q1 		$1.22M Buy
+21,600
New +$1.24M 0.01% 667

Other funds holding SWTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

UBS O'Connor's SWTX Position: Q3 2025 in Review

UBS O'Connor sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 1,385,517 shares — an estimated $65.1M sold.

UBS O'Connor first reported a position in SWTX in Q1 2022 and held it in 14 quarters. The position peaked at $65.1M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

  • UBS O'Connor reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 1,385,517 SpringWorks Therapeutics shares in Q3 2025, an estimated $65.1M.
  • UBS O'Connor first reported a position in SpringWorks Therapeutics in Q1 2022 and held it in 14 quarters.
  • UBS O'Connor's SpringWorks Therapeutics position peaked at $65.1M in Q2 2025.
  • 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.